{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T21:15:34Z","timestamp":1785532534205,"version":"3.56.0"},"reference-count":19,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2021-0148_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Various studies have shown that good quality of life (QoL) can be achieved after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). There is prognostic value of baseline QoL in post-operative outcome in Western setting. Our prospective study aims to validate these observations and elucidate clinical factors that predict poorer QoL in Asian peritoneal carcinomatosis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0148_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire was\u00a0administered to patients before CRS and HIPEC and thereafter at 3, 6 and 12\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0148_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 151 patients underwent 155 surgeries. Four hundred and seventy two questionnaires were completed. Median disease-free survival (DFS) was 16.5\u00a0months. Three year DFS and overall survival (OS) were 24.0% and 73.0% respectively. Post-operative global health status significantly increased at 3, 6 and 12 months. The decreases in functional scales recovered to baseline by 1-year post-surgery. Peritoneal carcinomatosis index (PCI), presence of stoma, peritonectomy duration, death within one year, post-operative complication and length of SICU stay negatively influenced QoL. Complication rates were higher in patients with lower global health status, physical and role functioning scores and higher symptom summary scores at baseline. Lower social functioning score, and higher pain, dyspnoea and symptom summary scores at baseline were significantly associated with poorer OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0148_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Various clinical factors can help us predict a patient\u2019s QoL after surgery. Several baseline factors were also able to predict morbidity and survival. Going forward, we can use these factors to help us better select patients who will have a greater benefit from CRS and HIPEC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2021-0148","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:09:01Z","timestamp":1649074141000},"page":"63-75","source":"Crossref","is-referenced-by-count":3,"title":["Can baseline quality of life scores predict for morbidity and survival after CRS and HIPEC: a prospective study of 151 patients"],"prefix":"10.1515","volume":"7","author":[{"given":"Claramae Shulyn","family":"Chia","sequence":"first","affiliation":[{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , Singapore General Hospital , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Oncology Academic Clinical Program, Duke-NUS Medical School , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Surgery Academic Clinical Program, Duke-NUS Medical School , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Ann Johnny","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , Singapore General Hospital , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Oncology Academic Clinical Program, Duke-NUS Medical School , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Surgery Academic Clinical Program, Duke-NUS Medical School , Singapore , Singapore"},{"name":"Laboratory of Applied Human Genetics, Division of Medical Sciences , National Cancer Centre Singapore , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , Singapore General Hospital , Singapore , Singapore"},{"name":"Laboratory of Applied Human Genetics, Division of Medical Sciences , National Cancer Centre Singapore , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Epidemiological Sciences , National Cancer Centre Singapore , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene Si Min","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , Singapore General Hospital , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Oncology Academic Clinical Program, Duke-NUS Medical School , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Surgery Academic Clinical Program, Duke-NUS Medical School , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Hwei Ching","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , Singapore General Hospital , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Ching Ching","family":"Teo","sequence":"additional","affiliation":[{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology , Singapore General Hospital , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Oncology Academic Clinical Program, Duke-NUS Medical School , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Surgery Academic Clinical Program, Duke-NUS Medical School , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"2025120909241453632_j_pp-2021-0148_ref_001","doi-asserted-by":"crossref","unstructured":"Chua, TC, Yan, TD, Saxena, A, Morris, DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 2009;249:900\u20137. https:\/\/doi.org\/10.1097\/SLA.0b013e3181a45d86.","DOI":"10.1097\/SLA.0b013e3181a45d86"},{"key":"2025120909241453632_j_pp-2021-0148_ref_002","doi-asserted-by":"crossref","unstructured":"McQuellon, RP, Loggie, BW, Fleming, RA, Russell, GB, Lehman, AB, Rambo, TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001;27:65\u201373. https:\/\/doi.org\/10.1053\/ejso.2000.1033.","DOI":"10.1053\/ejso.2000.1033"},{"key":"2025120909241453632_j_pp-2021-0148_ref_003","doi-asserted-by":"crossref","unstructured":"McQuellon, RP, Danhauer, SC, Russell, GB, Shen, P, Fenstermaker, J, Stewart, JH, et al.. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2007;14:1105\u201313. https:\/\/doi.org\/10.1245\/s10434-006-9304-5.","DOI":"10.1245\/s10434-006-9304-5"},{"key":"2025120909241453632_j_pp-2021-0148_ref_004","doi-asserted-by":"crossref","unstructured":"McQuellon, RP, Loggie, BW, Lehman, AB, Russell GB, GB, Fleming RA, RA, Shen, P, et al.. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003;10:155\u201362. https:\/\/doi.org\/10.1245\/aso.2003.03.067.","DOI":"10.1245\/ASO.2003.03.067"},{"key":"2025120909241453632_j_pp-2021-0148_ref_005","doi-asserted-by":"crossref","unstructured":"Schmidt, U, Dahlke, MH, Klempnauer, J, Schlitt, HJ, Piso, P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005;31:53\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2004.09.011.","DOI":"10.1016\/j.ejso.2004.09.011"},{"key":"2025120909241453632_j_pp-2021-0148_ref_006","doi-asserted-by":"crossref","unstructured":"Tuttle, TM, Zhang, Y, Greeno, E, Knutsen, A. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2006;13:1627\u201332. https:\/\/doi.org\/10.1245\/s10434-006-9186-6.","DOI":"10.1245\/s10434-006-9186-6"},{"key":"2025120909241453632_j_pp-2021-0148_ref_007","doi-asserted-by":"crossref","unstructured":"Leimk\u00fchler, M, Hentzen, JEKR, Hemmer, PHJ, Been, LB, van Ginkel, RJ, Kruijff, S, et al.. Systematic review of factors affecting quality of life after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2020;27:3973\u201383. https:\/\/doi.org\/10.1245\/s10434-020-08379-9.","DOI":"10.1245\/s10434-020-08379-9"},{"key":"2025120909241453632_j_pp-2021-0148_ref_008","doi-asserted-by":"crossref","unstructured":"Ihemelandu, CU, McQuellon, R, Shen, P, Stewart, JH, Votanopoulos, K, Levine, EA. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. Ann Surg Oncol 2013;20:3519\u201326. https:\/\/doi.org\/10.1245\/s10434-013-3049-8.","DOI":"10.1245\/s10434-013-3049-8"},{"key":"2025120909241453632_j_pp-2021-0148_ref_009","doi-asserted-by":"crossref","unstructured":"Dodson, RM, McQuellon, RP, Mogal, HD, Duckworth, KE, Russell, GB, Votanopoulos, KI, et al.. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2016;23:772\u201383. https:\/\/doi.org\/10.1245\/s10434-016-5547-y.","DOI":"10.1245\/s10434-016-5547-y"},{"key":"2025120909241453632_j_pp-2021-0148_ref_010","doi-asserted-by":"crossref","unstructured":"Tan, W, Wong, JA, Chia, SL, Tan, GH, Soo, KC, Teo, MC, et al.. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an Asian perspective. Ann Surg Oncol 2013;20:4219\u201323. https:\/\/doi.org\/10.1245\/s10434-013-3133-0.","DOI":"10.1245\/s10434-013-3133-0"},{"key":"2025120909241453632_j_pp-2021-0148_ref_011","doi-asserted-by":"crossref","unstructured":"Saxton, A, Velanovich, V. Preoperative frailty and quality of life as predictors of postoperative complications. Ann Surg 2011;253:1223\u20139. https:\/\/doi.org\/10.1097\/SLA.0b013e318214bce7.","DOI":"10.1097\/SLA.0b013e318214bce7"},{"key":"2025120909241453632_j_pp-2021-0148_ref_012","doi-asserted-by":"crossref","unstructured":"Anthony, T, Hynan, LS, Rosen, D, Kim, L, Nwariaku, F, Jones, C, et al.. The association of pretreatment health-related quality of life with surgical complications for patients undergoing open surgical resection for colorectal cancer. Ann Surg 2003;238:690\u20136. https:\/\/doi.org\/10.1097\/01.sla.0000094304.17672.6e.","DOI":"10.1097\/01.sla.0000094304.17672.6e"},{"key":"2025120909241453632_j_pp-2021-0148_ref_013","doi-asserted-by":"crossref","unstructured":"Mierzynska, M, Piccinin, C, Pe, M, Martinelli, F, Gotay, C, Coens, C, et al.. Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review. Lancet Oncol 2019;20:e683-96. https:\/\/doi.org\/10.1016\/S1470-2045(19)30656-4.","DOI":"10.1016\/S1470-2045(19)30656-4"},{"key":"2025120909241453632_j_pp-2021-0148_ref_014","doi-asserted-by":"crossref","unstructured":"Uwer, L, Rotonda, C, Guillemin, F, Miny, J, Kaminsky, MC, Mercier, M, et al.. Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer. Health Qual Life Outcome 2011;9:70. https:\/\/doi.org\/10.1186\/1477-7525-9-70.","DOI":"10.1186\/1477-7525-9-70"},{"key":"2025120909241453632_j_pp-2021-0148_ref_015","doi-asserted-by":"crossref","unstructured":"Teo, MCC, Tan, GHC, Tham, CK, Lim, C, Soo, KC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution. Ann Surg Oncol 2013;20:2968\u201374. https:\/\/doi.org\/10.1245\/s10434-013-2947-0.","DOI":"10.1245\/s10434-013-2947-0"},{"key":"2025120909241453632_j_pp-2021-0148_ref_016","doi-asserted-by":"crossref","unstructured":"Hinz, A, Einenkel, J, Briest, S, Stolzenburg, J-U, Papsdorf, K, Singer, S. Is it useful to calculate sum scores of the quality of life questionnaire EORTC QLQ-C30? Eur J Cancer Care 2012;21:677\u201383. https:\/\/doi.org\/10.1111\/j.1365-2354.2012.01367.x.","DOI":"10.1111\/j.1365-2354.2012.01367.x"},{"key":"2025120909241453632_j_pp-2021-0148_ref_017","doi-asserted-by":"crossref","unstructured":"Chia, CS, Tan, GHC, Lim, C, Soo, KC, Teo, MCC. Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2016;23:2905\u201313. https:\/\/doi.org\/10.1245\/s10434-016-5203-6.","DOI":"10.1245\/s10434-016-5203-6"},{"key":"2025120909241453632_j_pp-2021-0148_ref_018","doi-asserted-by":"crossref","unstructured":"Passot, G, Bakrin, N, Roux, AS, Vaudoyer, D, Gilly, FN, Glehen, O, et al.. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol 2014;40:529\u201335. https:\/\/doi.org\/10.1016\/j.ejso.2013.11.019.","DOI":"10.1016\/j.ejso.2013.11.019"},{"key":"2025120909241453632_j_pp-2021-0148_ref_019","doi-asserted-by":"crossref","unstructured":"Chia, CS, Tan, WJ, Wong, J, Tan, GH, Lim, C, Wang, W, et al.. Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2014;40:909\u201316. https:\/\/doi.org\/10.1016\/j.ejso.2013.12.028.","DOI":"10.1016\/j.ejso.2013.12.028"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0148\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0148\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:02:45Z","timestamp":1765278165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0148\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,15]]},"published-print":{"date-parts":[[2022,6,3]]}},"alternative-id":["10.1515\/pp-2021-0148"],"URL":"https:\/\/doi.org\/10.1515\/pp-2021-0148","relation":{},"ISSN":["2364-768X"],"issn-type":[{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]}}}